Literature DB >> 21402621

Palliative chemotherapy during the last month of life.

U Näppä1, O Lindqvist, B H Rasmussen, B Axelsson.   

Abstract

BACKGROUND: This study analyses the potential discriminative characteristics for patients with incurable cancer who received palliative chemotherapy during their last month of life. PATIENTS AND METHODS: The study includes all patients with epithelial cancer treated with palliative chemotherapy who died in 2008 in northern Sweden. Demographic parameters and care utilization data were registered. Data were analyzed using nonparametric methods.
RESULTS: Of 374 included patients, 87 (23%) received chemotherapy during the last month of life. These patients had a significantly shorter survival time from first palliative treatment to death, were admitted more frequently to hospital, more often lacked a documented decision to cease treatment, and died less frequently at home.
CONCLUSIONS: The results indicate covariations between palliative chemotherapy treatments in the last month of life and unfavorable patient outcomes. As almost one of four patients with incurable cancer received their last round of palliative chemotherapy <31 days before death, there is a potential for improved routines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402621     DOI: 10.1093/annonc/mdq778

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  47 in total

Review 1.  Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.

Authors:  Tito Fojo; Laleh Amiri-Kordestani; Susan E Bates
Journal:  J Natl Cancer Inst       Date:  2011-11-01       Impact factor: 13.506

2.  Chemotherapy in patients with advanced pancreatic cancer: too close to death?

Authors:  M Frigeri; S De Dosso; O Castillo-Fernandez; K Feuerlein; H Neuenschwander; P Saletti
Journal:  Support Care Cancer       Date:  2012-06-01       Impact factor: 3.603

Review 3.  Chemotherapy at end-of-life: an integration of oncology and palliative team.

Authors:  Wing-lok Chan; Ka-on Lam; Wai-kwan Siu; Kwok-keung Yuen
Journal:  Support Care Cancer       Date:  2015-11-25       Impact factor: 3.603

4.  Chemotherapy in the last 30 days of life of advanced cancer patients.

Authors:  Paola Pacetti; Giovanni Paganini; Massimo Orlandi; Andrea Mambrini; M Cristina Pennucci; Alfonso Del Freo; Maurizio Cantore
Journal:  Support Care Cancer       Date:  2015-04-22       Impact factor: 3.603

5.  End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer.

Authors:  Yingming Zhu; Ke Tang; Fen Zhao; Yuanwei Zang; Xiaodong Wang; Zhenxiang Li; Xindong Sun; Jinming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-29       Impact factor: 4.553

6.  Variation in medication use in cancer patients at the end of life: a cross-sectional analysis.

Authors:  N J H Raijmakers; L van Zuylen; C J Furst; M Beccaro; L Maiorana; P Pilastri; C Rossi; G Flego; A van der Heide; M Costantini
Journal:  Support Care Cancer       Date:  2012-10-14       Impact factor: 3.603

7.  Specific anticancer treatments in the last 3 months of life: a French experience.

Authors:  Erika Viel; Loïc Chaigneau; Eleonor Fanton; Elsa Kalbacher; Antoine Thiery-Vuillemnin; Cristian Villanueva; Erion Dobi; Elsa Curtit; Hamadi Almotlak; Régis Aubry; Xavier Pivot
Journal:  Support Care Cancer       Date:  2012-06-27       Impact factor: 3.603

8.  Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?

Authors:  Gianmauro Numico; Antonio Trogu; Antonella Cristofano; Alessandro Mozzicafreddo; Giulia Courthod; Pierfrancesco Franco; Nicola Silvestris
Journal:  Support Care Cancer       Date:  2014-05-11       Impact factor: 3.603

9.  Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

Authors:  Manabu Hayama; Hidekazu Suzuki; Takayuki Shiroyama; Motohiro Tamiya; Norio Okamoto; Ayako Tanaka; Naoko Morishita; Takuji Nishida; Takashi Nishihara; Tomonori Hirashima
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

10.  Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer.

Authors:  Aju Mathew; Tala Achkar; Shira Abberbock; Gurprataap S Sandhu; Mini Elizabeth Jacob; Vipin Das Villgran; Margaret Q Rosenzweig; Shannon Puhalla; Adam M Brufsky
Journal:  Breast J       Date:  2017-08-28       Impact factor: 2.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.